Headquartered in One Central Plaza, Dublin Fiscal year ends December NASDAQ: AMRN amarincorp.com
Amarin Corporation is a pharmaceutical company focused on advancing cardiovascular disease prevention worldwide. Its flagship oral prescription therapy, VASCEPA (icosapent ethyl, or IPE), marketed as VAZKEPA in Europe, is the first FDA-approved treatment comprised solely of icosapent ethyl, a unique form of eicosapentaenoic acid. VASCEPA is approved both for reducing cardiovascular risk in high-risk statin-treated patients with elevated triglycerides and for treating severe hypertriglyceridemia. The company operates an independent U.S. commercial organization while leveraging global partnerships, most notably with Recordati S.p.A. for 59 European and adjacent markets with patent protection through 2039. VASCEPA/VAZKEPA is commercially available in 22 countries and has been prescribed more than 32 million times globally. Amarin maintains a 47% share of the U.S. IPE market despite generic competition. The company is also exploring potential new therapeutic applications for IPE, including in oncology through investigator-initiated studies such as the EMT2 trial evaluating VASCEPA as an add-on therapy in colorectal cancer liver metastases. Amarin trades on NASDAQ under the ticker AMRN and operates with a debt-free balance sheet. Updated
The restructuring is now what drives Amarin: a 44% cut to operating expenses flipped it to net income of $245,000 from a year-ago loss, clearing the EPS consensus even as revenue missed expectations. Barclays is running a strategic review.
Friday’s additional top analyst upgrades and downgrades were on Amarin, Ardely, Ball, Coupang, Hanesbrands, United Airlines, Vimeo and more.
Wednesday's top analyst upgrades and downgrades included DraftKings, Dollar General, Hewlett Packard Enterprise, Novavax, Rackspace, Unity Software and Weyerhaeuser.
Amarin reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its blockbuster drug Vascepa.
Chris Lange Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly reduce cardiovascular risk in people with diabetes.
Among the items on the annual shareholders meeting agenda are the usual proposals. The board also has submitted a new stock incentive plan to replace the existing one that expires next year.
Paul Ausick Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
While Amarin supports research into Vascepa's possible use in treating COVID-19, the financial benefits promise to be greater if Vascepa's patents are upheld. Of course, Wall Street is bound to lift the…
Paul Ausick Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting…
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says.…
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin…
Amarin Corporation is a pharmaceutical company focused on advancing cardiovascular disease prevention worldwide.
The Wall Street consensus 12-month price target for AMRN is $12.50.
